Freenome FRNM 深 滬
等待開盤 10-29 09:30:00 美东时间
13.44
+0.400
+3.07%
華盛通- 最 高13.71
- 今 開13.05
- 成交量 49.58万股
- 最 低 13.05
- 昨 收 13.04
- 總市值 14.44亿
- 52周最高 17.50
- 市盈率 靜 177.54
- 換手率 0.46%
- 52周最低 9.97
- 委 比 84.47%
- 總股本 1.07亿
- 歷史最高 17.50
- 量 比 1.00
- 振 幅 5.06%
- 歷史最低 9.97
- 每 手 1
- 風險率 1.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Freenome Unveils SimpleScreen Lung Enabling Patients To Be Screened For Lung And Colorectal Cancer Through Single Blood Draw, Using Two Independently Validated, Indication-Specific Tests
– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw – – In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value for lung cancer in its intended use population...
10-20 20:34
木头姐ARK最新调仓曝光：继续加仓CoreWeave，买入近1900万美元Iambic股票，减持亚马逊、Palantir
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-16 15:09
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Freenome announced an updated version of its SimpleScreen™ CRC blood-based screening test, showing improved sensitivity for detecting advanced precancerous lesions (APLs) and maintaining 80.4% sensitivity for colorectal cancer (CRC) at 90% specificity. The updated test demonstrated 18.2% sensitivity for APLs, up from 13.7%, and 41.9% for APLs with high-grade dysplasia (HGD), compared to 30.5% previously. Improvements were seen across all APL subt...
10-11 17:00
Abbott launches "SimpleScreen" blood test to expand cancer screening
Abbott Laboratories (ABT) announced on Wednesday that it launched SimpleScreen CRC in the U.S., an FDA-approved blood test to screen for colorectal cancer in adults 45+ at average risk. The test, deve...
09-30 20:35
美股大行评级 | 潜在涨幅167.3%！HC Wainwright上调Tango Therapeutics目标价至68美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Tango Therapeutics"买入"评级，目标价从66美元升至68美元；康托·菲茨杰拉德：维持Duos Technologies Group"超配"评级，目标价从26美元升至27美元
08-19 08:37
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Leerink Partners Initiates Coverage On Freenome with Outperform Rating, Announces Price Target of $18
Leerink Partners analyst Puneet Souda initiates coverage on Freenome (NASDAQ:FRNM) with a Outperform rating and announces Price Target of $18.
08-15 00:27
